Author:
Williams Justin N.,Sankar Uma
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism
Reference71 articles.
1. Yelin EH, Cisternas M. Annual all-cause and incremental direct costs for all musculoskeletal diseases in current and 2014 dollars, United States 1996-2014. The burden of musculoskeletal diseases in the united States 2017.
2. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or Zoledronic acid in postmenopausal women with osteoporosis previously treated with Oral bisphosphonates. J Clin Endocrinol Metab. 2016;101(8):3163–70.
https://doi.org/10.1210/jc.2016-1801
.
3. Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. P T. 2018;43(2):92–104.
4. Jin A, Cobb J, Hansen U, Bhattacharya R, Reinhard C, Vo N, et al. The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density. Bone Joint Res. 2017;6(10):602–9.
https://doi.org/10.1302/2046-3758.610.BJR-2016-0321.R1
.
5. Miller PD, Hattersley G, Lau E, Fitzpatrick LA, Harris AG, Williams GC, et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial. Bone. 2018;120:137–40.
https://doi.org/10.1016/j.bone.2018.10.015
.